Hoth Therapeutics (HOTH) 10-K 28 Mar 24 2023 FY Annual report Financial data

Cover

Cover - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Mar. 26, 2024	Jun. 30, 2023
Document Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Transition Report	false
Document Financial Statement Error Correction [Flag]	false
Entity Interactive Data Current	Yes
ICFR Auditor Attestation Flag	false
Amendment Flag	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Documents Incorporated by Reference [Text Block]	None
Entity Information [Line Items]
Entity Registrant Name	HOTH THERAPEUTICS, INC.
Entity Central Index Key	0001711786
Entity File Number	001-38803
Entity Tax Identification Number	82-1553794
Entity Incorporation, State or Country Code	NV
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Public Float			$ 9.8
Entity Incorporation, Date of Incorporation	May 16, 2017
Entity Contact Personnel [Line Items]
Entity Address, Address Line One	590 Madison Ave
Entity Address, Address Line Two	21st Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10022
Entity Phone Fax Numbers [Line Items]
City Area Code	(646)
Local Phone Number	756-2997
Entity Listings [Line Items]
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	HOTH
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		4,403,804

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2023
Auditor [Table]
Auditor Name	WithumSmith+Brown, PC
Auditor Firm ID	100
Auditor Location	New York

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash	$ 9,292,352	$ 6,428,611
Marketable equity securities, at fair value		209,320
Prepaid expenses and other current assets	135,361	88,450
Total current assets	9,427,713	6,726,381
Right of use asset – operating lease	55,165
Investment in joint ventures at fair value	37,400	33,000
Total assets	9,520,278	6,759,381
Current liabilities:
Accounts payable	35,592	694,989
Accrued expenses	614,226	667,742
Accrued license fee - current portion		25,000
Lease liability, current	28,839
Total current liabilities	678,657	1,387,731
Lease liability, noncurrent	26,326
Accrued license fee - less current portion		250,000
Total liabilities	704,983	1,637,731
Commitments and Contingencies (See Note 7)
Stockholders’ equity:
Preferred stock, value
Common stock, $0.0001 par value, 50,000,000 shares authorized, 4,348,129 and 1,302,113 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	435	130
Additional paid-in capital	61,732,106	50,198,630
Accumulated deficit	(52,944,506)	(45,099,116)
Accumulated other comprehensive income	27,260	22,006
Total stockholders’ equity	8,815,295	5,121,650
Total liabilities and stockholders’ equity	9,520,278	6,759,381
Series A Convertible Preferred Stock
Stockholders’ equity:
Preferred stock, value
Series B Preferred Stock
Stockholders’ equity:
Preferred stock, value

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Preferred stock, shares undesignated (in Dollars per share)	$ 3,000,000	$ 3,000,000
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	4,348,129	1,302,113
Common stock, shares outstanding	4,348,129	1,302,113
Series A Convertible Preferred Stock
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Preferred stock, shares designated (in Dollars per share)	$ 5,000,000	$ 5,000,000
Series B Preferred Stock
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Preferred stock, shares designated (in Dollars per share)	$ 2,000,000	$ 2,000,000

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating costs and expenses
Research and development	$ 3,480,053	$ 4,931,164
General and administrative expenses	4,212,189	6,134,390
Total operating expenses	7,692,242	11,065,554
Loss from operations	(7,692,242)	(11,065,554)
Other income (expense), net
Unrealized gain (loss) on marketable securities	(209,320)	119,870
Realized loss on marketable securities		(567,692)
Change in fair value of investments in joint ventures	4,400	(377,000)
Interest income	781	6,370
Dividend income	50,991	60,913
Other income, net		451,140
Total other income (expense), net	(153,148)	(306,399)
Net loss	(7,845,390)	(11,371,953)
Deemed dividend to Series B Preferred Stock being redeemed		990
Net Loss Attributable to Common Stockholders	$ (7,845,390)	$ (11,370,963)
Net loss per share - basic (in Dollars per share)	$ (2.3)	$ (9.5)
Weighted average number of common shares outstanding, basic (in Shares)	3,409,190	1,197,521
Comprehensive loss:
Net loss	$ (7,845,390)	$ (11,371,953)
Other comprehensive income
Foreign currency translation adjustment	5,254	4,420
Total comprehensive loss	$ (7,840,136)	$ (11,367,533)

Consolidated Statements of Op_2

Consolidated Statements of Operations and Comprehensive Loss (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Net loss per share diluted	$ (2.30)	$ (9.50)
Weighted average number of common shares outstanding, diluted	3,409,190	1,197,521

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders’ Equity - USD ($)	Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Total
Balance at Dec. 31, 2021		$ 96	$ 43,591,773	$ (33,727,163)	$ 17,586	$ 9,882,292
Balance (in Shares) at Dec. 31, 2021		959,009
Stock-based compensation			620,798			620,798
Stock-based compensation (in Shares)		10
Vesting of restricted stock awards
Vesting of restricted stock awards (in Shares)		1,791
Issuance of common stock (net of offering costs of $1,014,896)		$ 33	5,985,070			5,985,103
Issuance of common stock (net of offering costs of $1,014,896) (in Shares)		329,412
Issuance of Series B preferred stock	$ 1,000					1,000
Issuance of Series B preferred stock (in Shares)	2,000,000
Redemption of Series B preferred stock	$ (1,000)		990			(10)
Redemption of Series B preferred stock (in Shares)	(2,000,000)
Fractional shares adjusted for reverse split		$ 1	(1)
Fractional shares adjusted for reverse split (in Shares)		11,891
Cumulative translation adjustment					4,420	4,420
Net loss				(11,371,953)		(11,371,953)
Balance at Dec. 31, 2022		$ 130	50,198,630	(45,099,116)	22,006	5,121,650
Balance (in Shares) at Dec. 31, 2022		1,302,113
Exercise of warrants		$ 236	2,119			2,355
Exercise of warrants (in Shares)		2,355,050
Common stock and warrants issued in private placement (net of offering costs of $1,575,645)		$ 69	11,314,929			11,314,998
Common stock and warrants issued in private placement (net of offering costs of $1,575,645) (in Shares)		689,275
Stock-based compensation			216,428			216,428
Stock-based compensation (in Shares)
Vesting of restricted stock awards
Vesting of restricted stock awards (in Shares)		1,691
Cumulative translation adjustment					5,254	5,254
Net loss				(7,845,390)		(7,845,390)
Balance at Dec. 31, 2023		$ 435	$ 61,732,106	$ (52,944,506)	$ 27,260	$ 8,815,295
Balance (in Shares) at Dec. 31, 2023		4,348,129

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Stockholders’ Equity (Parentheticals) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Statement of Stockholders' Equity [Abstract]
Issuance of common stock net of offering costs	$ 1,575,645	$ 1,014,896

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities
Net loss	$ (7,845,390)	$ (11,371,953)
Adjustments to reconcile net loss to net cash used in operating activities:
Research and development-acquired license, expensed		34,000
Gain on termination of license agreement	(275,000)
Change in fair value of investments in joint ventures	(4,400)	377,000
Stock-based compensation	216,428	620,798
Realized loss on marketable securities		567,692
Unrealized (gain) loss on marketable securities	209,320	(119,870)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(47,300)	3,847
Accounts payable and accrued expenses	(700,752)	590,632
Net cash used in operating activities	(8,447,094)	(9,297,854)
Cash flows from investing activities
Purchase of research and development licenses		(74,000)
Sale of marketable securities		1,235,695
Net cash provided by investing activities		1,161,695
Cash flows from financing activities
Proceeds from issuance common stock, common stock warrants and prefunded warrants, net of offering costs	11,314,998
Proceeds from exercise of warrants	2,355
Proceeds from issuance common stock, net of offering costs		5,985,103
Proceeds from issuance of Series B Preferred Stock		1,000
Redemption of Series B Preferred Stock		(10)
Proceeds from repayment of note receivable and interest received		50,000
Net cash provided by financing activities	11,317,353	6,036,093
Effect of exchange rate changes on cash and cash equivalents	(6,518)	(9,593)
Net change in cash	2,870,259	(2,100,066)
Cash, beginning of year	6,428,611	8,538,270
Cash, end of year	9,292,352	6,428,611
Supplemental disclosure of cash flow information:
ROU assets obtained in exchange for lease liability	$ 59,698

Organization and Description of

Organization and Description of Business Operations	12 Months Ended
	Dec. 31, 2023
Organization and Description of Business Operations [Abstract]
Organization and Description of Business Operations	Note 1-Organization and description of business operations Hoth Therapeutics, Inc. (together with its wholly-owned subsidiaries, merveille.ai and Hoth Therapeutics Australia Pty Ltd, the “Company”) was incorporated under the laws of the State of Nevada on May 16, 2017. The Company is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. The Company is focused on developing (i) a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); (ii) a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); (iii) a treatment for traumatic brain injury and ischemic stroke (HT-TBI); and (iv) a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). We also have assets being developed for (i) atopic dermatitis (also known as eczema) (BioLexa); (ii) a treatment for asthma and allergies using inhalational administration (HT-004); and (iii) a treatment for acne as well as inflammatory bowel diseases (HT-003). The Company also has interests in certain other assets being developed by third parties (see Note 5 to the consolidated financial statements for a discussion of the Company’s agreement with Zylö Therapeutics, Inc. and Voltron Therapeutics, Inc.). Liquidity and capital resources Accounting Standards Update (“ASU”) No. 2014-15, Presentation of Financial Statements - Going Concern, requires management to evaluate the Company’s ability to continue as a going concern one year beyond the filing date of the given financial statements. This evaluation requires management to perform two steps. First, management must evaluate whether there are conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern. Second, if management concludes that substantial doubt is raised, management is required to consider whether it has plans in place to alleviate that doubt. Disclosures in the notes to the consolidated financial statements are required if management concludes that substantial doubt exists or that its plans alleviate the substantial doubt that was raised. The Company has funded its operations from proceeds from the sale of equity and debt securities. The Company will require significant additional capital to make the investments it needs to execute its longer-term business plan. The Company’s ability to successfully raise sufficient funds through the sale of debt or equity securities when needed is subject to many risks and uncertainties and, even if it were successful, future equity issuances may result in dilution to its existing shareholders and future debt securities may contain covenants that limit the Company’s operations or ability to enter into certain transactions. The Company believes its current cash is sufficient to fund operations for at least the next 12 months from the issuance date of these financial statements. However, the Company will need to raise additional funding, through strategic relationships, public or private equity or debt financings, grants or other arrangements, to develop and seek regulatory approvals for the Company’s current and future product candidates. If such funding is not available, or not available on terms acceptable to the Company, the Company’s current development plan and plans for expansion of its general and administrative infrastructure may be curtailed. On September 13, 2023, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which it sold (i) 549,275 shares of common stock and (ii) pre-funded warrants (the “September Pre-Funded Warrants”) to purchase up to 550,725 shares of common stock at a purchase price of $2.63 per share of common stock and a purchase price of $2.629 per September Pre-Funded Warrant. Concurrently with the sale of common stock and/or the September Pre-Funded Warrants, pursuant to the in a private placement, the Company issued and sold prior to deducting placement agent’s fees and other offering expenses payable by the Company

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Significant Accounting Policies [Abstract]
Significant accounting policies	Note 2-Significant accounting policies Basis of presentation and principles of consolidation The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying consolidated financial statements include the accounts of the Company’s wholly-owned subsidiaries, merveille.ai which was incorporated under the laws of Nevada on October 4, 2023 and Hoth Therapeutics Australia Pty Ltd, which was incorporated under the laws of the State of Victoria in Australia on June 5, 2019. All significant intercompany balances and transactions have been eliminated in consolidation. Reclassifications Certain line items on the statement of operations and comprehensive loss for the year ended December 31, 2022 have been reclassified to conform to the current period presentation. Research and development - licenses acquired (including stock-based compensation) of $0.1 million was reclassified to research and development. Compensation and related expenses (including stock-based compensation) of $2.6 million, professional fees (including stock-based compensation) of $2.5 million, rent of $0.1 million, and other general and administrative expense of $1.0 million were consolidated into one general and administrative line item. Dividend income and realized and unrealized gains and losses have been separately presented within other income (expense), net. These reclassifications did not change our reported net loss or comprehensive loss for the year ended December 31, 2022. Emerging growth company As an emerging growth company, the Company may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act of 1933, as amended, registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statement with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. However, beginning December 31, 2024, we will no longer be an “emerging growth company,” and will no longer have the ability to delay adoption of these new or revised accounting standards, or to take advantage of reduced corporate governance disclosures. Use of estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company’s consolidated financial statements relate to stock-based compensation and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. Cash and cash equivalents The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents. There were no cash equivalents as of December 31, 2023 and December 31, 2022, respectively. Cash held in foreign bank accounts totaled $0.1 million and $0.4 million as of December 31, 2023 and December 31, 2022, respectively. Marketable securities Marketable securities are classified as trading and are carried at fair value. The Company’s marketable securities consist of a mutual fund which is valued at a quoted market price. Concentrations of credit risk and off-balance sheet risk The Company has significant cash balances at financial institutions which, throughout the year, regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows. Fair Value of Financial Instruments Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurements The fair value of the Company’s assets and liabilities, which would qualify as financial instruments under ASC Topic 820, approximates the carrying amounts represented in the Company’s balance sheet, primarily due to their short-term nature. The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. During the years ended December 31, 2023 and December 31, 2022, there were no changes in valuation techniques or transfers between Level 1, Level 2, and Level 3. Leases The Company determines if an arrangement is a lease at inception and classifies its leases at commencement. Operating leases are presented as right-of-use (“ROU”) assets and the corresponding lease liabilities are included in lease liability, current and lease liability, on the Company’s balance sheets. ROU assets represent the Company’s right to use an underlying asset, and lease liabilities represent the Company’s obligation to make lease payments in exchange for the ability to use the asset for the duration of the lease term. The Company has lease agreements which contain both lease and non-lease components, which it has elected to account for as a single lease component. As such, minimum lease payments include fixed payments for non-lease components within a lease agreement but exclude variable lease payments not dependent on an index or rate, such as common area maintenance, operating expenses, utilities, or other costs that are subject to fluctuation from period to period. Certain of the leases contain an option to extend the term of the lease. The option to extend a lease is included in the lease term only when it is reasonably certain that the Company will elect that option. Additionally, the Company does not record ROU assets or lease liabilities for short-term leases that have a term of twelve months or less at lease commencement. ROU assets and lease liabilities are recognized at the commencement date and determined using the present value of the future minimum lease payments over the lease term. The Company uses an incremental borrowing rate based on an estimated rate of interest for collateralized borrowing since the Company’s leases do not include an implicit interest rate. The estimated incremental borrowing rate considers market data, actual lease economic environment, and the lease term at commencement date. Investment in joint ventures Ownership interests in entities for which the Company has significant influence that are not consolidated are accounted for as equity method investments. SEC Staff Announcement: “Accounting for Limited Partnership Investments” (codified in ASC 323-30-S99-1) guidance requires the use of the equity method unless the investor’s interest “is so minor that the limited partner may have virtually no influence over partnership operating and financial policies.” The SEC staff’s position is that investments in limited partnerships of greater than 3% to 5% are considered more than minor and, therefore, should be accounted for using the equity method or fair value option. Investments accounted for using the equity method may be reported on a lag up to three months if financial statements of the investee are not available in sufficient time for the investor to apply the equity method as of the current reporting date. The determination of whether an investee’s results are recorded on a lag is made on an investment-by-investment basis. This investment in joint ventures is further described in Note 5 of these consolidated financial statements. Accounts Payable For the year ended December 31, 2023, the Company’s subsidiary Hoth Therapeutics Australia Pty Ltd, recorded approximately a $260,000 gain due to a settlement agreement on a payable balance with Novotech, a clinical trial management vendor. The gain is recognized in the consolidated statements of operations and comprehensive loss following a manner consistent with how the expense was originally recorded. Research and development costs Research and development costs, including acquired in-process research and development expenses for which there is no alternative future use, are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Stock-based compensation The Company accounts for share-based payment awards exchanged for services at the estimated grant date fair value of the award. Stock options issued under the Company’s long-term incentive plans are granted with an exercise price equal to no less than the market price of the Company’s stock at the date of grant and expire up to ten years from the date of grant. Options are generally issued fully vested. The Company accounts for forfeited awards as they occur. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. Expected Term Expected Volatility Risk-Free Interest Rate Expected Dividend The Company grants restricted stock awards under its equity incentive plan. Restricted stock awards are granted to employees and non-employees. The restricted stock awards are measured based on the grant-date fair value. In general, the restricted stock awards vest over a service period of zero to three years. Stock-based compensation expense is generally recognized based on the straight-line basis over the requisite service period and forfeitures are accounted for as they occur. The Company has issued warrants to non-employees. The warrants are measured based on the grant-date fair value. In general, the warrants vest over a term of zero to ten years. Stock-based compensation expense is generally recognized based on the straight-line basis over the vesting term. Income taxes Income taxes are recorded in accordance with ASC 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. Net loss per share Net loss per share is computed by dividing net loss by the weighted average number of common stock outstanding during the period. Since the Company had a net loss in the periods presented, basic and diluted net loss per common share are the same. The following were excluded from the computation of diluted shares outstanding due to the losses for each period presented, as they would have had an anti-dilutive impact on the Company’s net loss: Year Ended December 31, Potentially dilutive securities 2023 2022 Warrants 4,213,515 402,840 Options 169,362 104,651 Non-vested restricted stock awards 1,693 3,384 Total 4,384,570 510,875 Recent accounting pronouncements Currently, management does not believe that any recently issued, but not yet effective accounting pronouncements, if currently adopted, would have a material impact on the Company’s consolidated financial statements.

License Agreements

License Agreements	12 Months Ended
	Dec. 31, 2023
License Agreements [Abstract]
License Agreements	Note 3-License Agreements The following summarizes the Company’s research and development expenses for licenses acquired during the years ended December 31, 2023 and 2022: Year Ended December 31, 2023 2022 The George Washington University $ 66,172 $ 66,586 North Carolina State University — 27,500 Virginia Commonwealth University (275,000 ) — University of Cincinnati 7,500 7,500 Adjustment — (15,000 ) $ (201,328 ) $ 86,586 The George Washington University During the year ended December 31, 2023, the Company recorded an expense of approximately $29,000 related to warrants granted to The George Washington University (“GW”) pursuant to the patent license agreement with GW dated February 1, 2020 (“GW Patent License Agreement”) and the patent license agreement with GW dated August 7, 2020 (“Second GW Patent License Agreement”). The Company recorded an expense of $30,000 for a milestone payment pursuant to GW Patent License Agreement. The Company also recorded $7,500 the year ended December 31, 2023 for license maintenance fees. During the year ended December 31, 2022, the Company recorded an expense of approximately $53,000 related to warrants granted to The George Washington University (“GW”) pursuant to the patent license agreement with GW dated February 1, 2020 (“GW Patent License Agreement”) and the patent license agreement with GW dated August 7, 2020 (“Second GW Patent License Agreement”). The Company also recorded $14,000 the year ended December 31, 2022 for license maintenance fees. North Carolina State University During the year ended December 31, 2023, the Company paid $0 for the license fee associated with the license agreement by and between the Company and North Carolina State University dated February 25, 2021. During the year ended December 31, 2022, the Company paid approximately $28,000 for the license fee associated with the license agreement by and between the Company and North Carolina State University dated February 25, 2021. Virginia Commonwealth University On August 16, 2023, the Company terminated its license agreement by and between the Company and Virginia Commonwealth University dated May 18, 2020. As of December 31, 2023, the Company reversed its prior accrual of $150,000 for five As of December 31, 2022, the Company accrued $150,000 for five years of annual minimum payments and $125,000 for annual maintenance fees. Chelexa Biosciences, Inc. and the University of Cincinnati During the year ended December 31, 2023, the Company paid $2,500 for the annual license maintenance fee and $5,000 for the minimum royalty fee to the University of Cincinnati associated with the Assignment and Assumption Agreement by and between the Company and Chelexa Biosciences dated May 14, 2020. During the year ended December 31, 2022, the Company paid $2,500 for the annual license maintenance fee and $5,000 for the minimum royalty fee associated to the University of Cincinnati with the Assignment and Assumption Agreement by and between the Company and Chelexa Biosciences dated May 14, 2020.

Note Receivable

Note Receivable	12 Months Ended
	Dec. 31, 2023
Note Receivable [Abstract]
Note Receivable	Note 4-Note Receivable Pursuant to the sublicense agreement dated July 30, 2020 by and between the Company and Isoprene Pharmaceuticals, Inc. (“Isoprene”), the Company made an investment of $50,000 in Isoprene in the form of a convertible promissory note (the “Isoprene Note”) on September 10, 2020. The Isoprene Note was due to mature on September 10, 2022 and accrued interest at a rate equal to the lower of: (i) the highest lawful rate permitted under applicable law and (ii) 6% per annum. The Isoprene Note could not be prepaid without the prior written consent of the Company; provided, however, that if the Isoprene Note had not been converted in connection with a Qualified Financing (as defined or a Change of Control (as defined) by the two year anniversary of the date of the issuance of the Isoprene Note, Isoprene could elect, in its sole discretion, to repay the Isoprene Note and any accrued interest thereon. As of the maturity date of the Isoprene Note, neither a Qualified Financing nor a Change of Control had occurred, and the Isoprene Note of $50,000 and accrued interest of approximately $6,000 was paid off on October 21, 2022.

Fair Value of Financial Assets

Fair Value of Financial Assets and Liabilities	12 Months Ended
	Dec. 31, 2023
Fair Value of Financial Assets and Liabilities [Abstract]
Fair Value of Financial Assets and Liabilities	Note 5-Fair Value of Financial Assets and Liabilities The following tables present the Company’s assets and liabilities that are measured at fair value at December 31, 2023 and 2022: Fair value measured at December 31, 2023 Total at Quoted Significant Significant Assets Marketable securities - mutual fund $ — $ — $ — $ — Investment in joint ventures $ 37,400 $ — $ — $ 37,400 Fair value measured at December 31, 2022 Total at Quoted (Level 1) Significant Significant (Level 3) Assets Marketable securities - mutual fund $ 209,320 $ 209,320 $ — $ — Investment in joint ventures $ 33,000 $ — $ — $ 33,000 Level 3 Measurement The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis: Investment in joint ventures at fair value at December 31, 2021 $ 410,000 Change in fair value of investments in joint ventures (377,000 ) Investment in joint ventures at fair value at December 31, 2022 33,000 Change in fair value of investments in joint ventures 4,400 Investment in joint ventures at fair value at December 31, 2023 $ 37,400 Investment in joint ventures The Company has elected to measure the investment in joint ventures using the fair value option at each reporting date. Under the fair value option, bifurcation of an embedded derivative is not necessary, and all related gains and losses on the host contract and derivative due to change in the fair value will be reflected in interest income and other income (expense), net in the consolidated statements of operations and comprehensive loss. The value at which the Company’s investment in joint ventures is carried on its books is adjusted to estimated fair value at the end of each quarter, taking into account general economic and stock market conditions and those characteristics specific to the underlying investments. Investment in HaloVax On March 23, 2020, the Company entered into a Development and Royalty Agreement (the “Development and Royalty Agreement”) with Voltron Therapeutics, Inc. (“Voltron”) to form a joint venture entity named HaloVax, LLC (“HaloVax”) to jointly develop potential product candidates for the prevention of COVID-19 based upon certain technology that had been exclusively licensed by Voltron from The General Hospital Corporation (d/b/a Massachusetts General Hospital). Pursuant to the Development and Royalty Agreement, the Company is entitled to receive sales-based royalties. In addition, pursuant to the terms of the Development and Royalty Agreement, on March 23, 2020, the Company and HaloVax entered into a Membership Interest Purchase Agreement pursuant to which the Company purchased 5% of HaloVax’s outstanding membership interests for $250,000 on March 27, 2020 (the “Initial Closing Date”) and had the option to purchase up to an additional 25% of HaloVax’s membership interests (for $3,000,000 (inclusive of the $250,000)), which option expired 30 days after the Initial Closing Date. On May 28, 2020, the Company entered into a Membership Interest Purchase Agreement to purchase 1% of HaloVax’s outstanding membership interest for a purchase price of $100,000. During the fourth quarter of 2022, the Company identified indicators of impairment for the HaloVax investment as a result of adverse changes in HaloVax’s business operations, including liquidity concerns. As a result, the Company recorded an impairment charge of approximately $0.4 million in the fourth quarter of 2022. The investment in HaloVax was valued at $0 as of December 31, 2023 and 2022. Investment in Zylö In connection with the Company’s March 2020 underwritten public offering of shares of its common stock, on May 4, 2020, the Company purchased 120,000 shares of Zylö’s Class B common stock for $60,000. On December 8, 2021, the Company entered into a third amendment (the “Zylö Amendment”) to the Exclusive Sublicense Agreement with Zylö originally dated August 19, 2019, pursuant to which the Company licensed its novel cannabinoid therapeutic, HT-005 for lupus patients, back to Zylö. Pursuant to the Zylö Amendment, on December 6, 2021, Zylö issued the Company 100,000 shares of its Class B common stock. In addition, pursuant to the Zylö Amendment, within 90 days following a sale by Zylö of all of its assets and rights related to HT-005 to a third-party (a “Sale”), Zylö shall pay the Company a low single digit percent of the net proceeds received by it attributable to HT-005 in the United States and Canada and their respective territories (collectively, the “Territory”) for the purposes of therapeutic uses related to lupus in humans (the “Field”). After the Sale, any and all rights of the Company pursuant to the Exclusive Sublicense Agreement, including all amendments thereto, shall terminate. Furthermore, pursuant to the Zylö Amendment, following the date of the first commercial sale of HT-005 in the Territory, in the Field, Zylö shall pay the Company (i) a low single digit percent of the Net Sales (as defined in the Exclusive Sublicense Agreement) of HT-005 in the event HT-005 is sold in the Territory and (ii) a low double digit percent of any royalty that Zylö receives through the sublicense to a third-party based on Net Sales of HT-005 in the Territory which payments shall continue in each country in the Territory until expiration of the last-to-expire Valid Claim (as defined in the Exclusive Sublicense Agreement). During December 2022, Zylö conducted a 409A valuation of their Class B common stock and valued its share price at $0.15 per share. This value was ratified by Zylö’s board of directors in December 2022. In December 2023, Zylö conducted a 409A valuation of their Class B common stock and valued its share price at $0.17 per share. This value was ratified by Zylö’s board of directors in December 2023. The valuation reflects a probability-weighted present value of expected future investment returns considering certain possible outcomes and the rights of each class of Zylö’s equity. The future values of the common stock under the various outcomes are discounted back to the valuation date at a risk-adjusted discount rate and probability weighted to determine the value for the Class B common stock. Significant unobservable inputs in the valuation include: (i) probabilities of each scenario, (ii) timing of occurrence, (iii) future valuation; (iv) and the risk-adjusted discount rate. During the years ended December 31, 2023 and 2022, the Company recorded approximately $4,400 in unrealized gain on this investment and $27,000 in unrealized loss on this investment, respectively. The investment in Zylö was valued at $37,400 and $33,000 as of December 31, 2023 and 2022, respectively.

Stockholder_s Equity

Stockholder’s Equity	12 Months Ended
	Dec. 31, 2023
Stockholder’s Equity [Abstract]
Stockholder’s Equity	Note 6-Stockholder’s Equity Preferred Stock The Company is authorized to issue up to 10,000,000 shares of preferred stock. This preferred stock may be issued in one or more series, and shall have such designations, preferences and relative, participating, optional or other special rights and qualifications, limitations or restrictions thereof as shall be determined at the time of issuance by the Company’s board of directors without further action by the Company’s shareholders. As of December 31, 2023, 5,000,000 shares of the Company’s preferred stock has been designated as Series A Convertible Preferred Stock and 2,000,000 shares of the Company’s preferred stock has been designated as Series B Preferred Stock. Series A Convertible Preferred Stock The shares of Series A Convertible Preferred Stock, par value $0.0001 per share, are not mandatorily redeemable and do not embody an unconditional obligation to settle in a variable number of equity shares. As such, the shares of Series A Convertible Preferred Stock are classified as permanent equity on the consolidated balance sheets. The holders’ contingent redemption right in the event of certain deemed liquidation events does not preclude permanent equity classification. Further, the shares of Series A Convertible Preferred Stock are considered an equity-like host for purposes of assessing embedded derivative features for potential bifurcation. The embedded conversion feature is considered to be clearly and closely related to the associated convertible preferred stock host instrument and therefore was not bifurcated from the equity host. Series B Preferred Stock On November 2, 2022, the Company filed a Certificate of Designation of the Series B Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Nevada to create a new class of Series B Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock”). The Certificate of Designation designated 2,000,000 shares of authorized preferred stock as Series B Preferred Stock. The Series B Preferred Stock were not entitled to receive dividends or any other distributions. The Series B Preferred Stock were entitled to ten votes per share and voted together with the Company’s issued and outstanding shares of common stock as a single class exclusively with respect to the Authorized Stock Increase (as defined herein). The Series B Preferred Stock had no rights as to any distribution or assets of the Company upon a liquidation, bankruptcy, reorganization, merger, acquisition, sale, dissolution or winding up of the Company. On November 2, 2022, the Company entered into a Subscription and Investment Representation Agreement with an investor pursuant to which the Company issued and sold 2,000,000 shares of its newly designated Series B Preferred Stock to such purchaser for an aggregate purchase price of $1,000. On December 12, 2022, the Company’s shareholders approved an increase to the number of authorized shares of the Company’s common stock from 3,000,000 to 50,000,000 shares (the “Authorized Stock Increase”). On December 13, 2022, upon filing a Certificate of Amendment to its Articles of Incorporation, as amended, to increase its authorized shares of common stock, the outstanding shares of Series B Preferred Stock were redeemed in whole for an aggregate price of $10 automatically and effective immediately after the effectiveness of the Authorized Stock Increase. Common Shares On December 12, 2022, shareholders of the Company approved an increase to the number of authorized shares of the Company’s common stock from 3,000,000 shares to 50,000,000 shares, and on December 13, 2022, the Company filed a Certificate of Amendment to its Articles of Incorporation, as amended, to effectuate such increase. Securities Purchase Agreements On September 13, 2023, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which it sold (i) 549,275 shares of common stock and (ii) pre-funded warrants (the “September Pre-Funded Warrants”) to purchase up to 550,725 shares of common stock at a purchase price of $2.63 per share of common stock and a purchase price of $2.629 per September Pre-Funded Warrant. Concurrently with the sale of common stock and/or the September Pre-Funded Warrants, pursuant to the in a private placement, the Company issued and sold prior to deducting placement agent’s fees and other offering expenses payable by the Company On December 29, 2022, the Company entered into a securities purchase agreement with an accredited investor pursuant to which it agreed to sell an aggregate of (i) 140,000 shares of common stock, (ii) December Pre-Funded Warrants to purchase up to 1,860,000 shares of common stock and (iii) December Common Stock Warrants to purchase up to 2,500,000 shares of common stock at a purchase price of $5.00 per share and accompanying warrant (less $0.001 for each December Pre-Funded Warrant and accompanying warrant) in a private placement for aggregate gross proceeds of approximately $10 million, exclusive of placement agent commission and fees and other offering expenses. The closing of the offering occurred on January 3, 2023. Each December Common Stock Warrant is exercisable for a period of five and one-half years from the issuance date at an exercise price of $5.00 per share, subject to adjustment, and may, under certain circumstances, be exercised on a cashless basis. Each December Pre-Funded Warrant is exercisable until exercised in full at an exercise price of $0.001 per share and may be exercised on a cashless basis. In addition, pursuant to the terms of the offering, the Company issued H.C. Wainwright & Co., LLC the December Wainwright Warrants to purchase up to 100,000 shares of the Company’s common stock. The December Wainwright Warrants are exercisable for a period of five and one-half years from the issuance date at an exercise price of $6.25 per share, subject to adjustment, and may, under certain circumstances, be exercised on a cashless basis. Public Offering of Securities On April 14, 2022, the Company closed an underwritten public offering of 329,412 shares of the Company’s common stock at a price to the public of $21.25 per share (the “Offering Price”). Pursuant to the terms of an underwriting agreement dated April 11, 2022 between the Company and EF Hutton, division of Benchmark Investments, LLC, as representative of the several underwriters (the “Underwriters”), the Company granted the Underwriters a 45-day option to purchase up to an additional 49,412 shares of the Company’s common stock to cover over-allotments, if any, at the Offering Price less the underwriting discounts and commissions. The net proceeds to the Company from the sale of the shares, after deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company, were $6.0 million. The Underwriters did not exercise their over-allotment option. 2018 Equity Incentive Plan The compensation committee of the board of directors increased the number of shares reserved pursuant to the Company’s 2018 Equity Incentive Plan (“2018 Plan”) by 26,878 shares effective as of January 1, 2021, such that as of January 1, 2021, the Company had an aggregate of 66,878 shares of common stock reserved for issuance pursuant to the 2018 Plan. On June 24, 2021, at the annual meeting of shareholders, shareholders of the Company approved an amendment to the 2018 Plan to further increase the number of shares reserved for issuance thereunder from 66,878 shares to 146,878 shares. On February 2, 2022, the compensation committee of the board of directors further increased the number of shares reserved for issuance under the 2018 Plan from 146,878 shares to 156,878 shares. On January 11, 2023, the compensation committee of the board of directors further increased the number of shares reserved for issuance under the 2018 Plan from 156,878 shares to 166,878 shares. On January 4, 2024, the compensation committee of the board of directors further increased the number of shares reserved for issuance under the 2018 Plan from 166,878 shares to 176,878 shares. 2022 Equity Incentive Plan On March 24, 2022, the Company’s board of directors adopted the Hoth Therapeutics, Inc. 2022 Omnibus Equity Incentive Plan (the “2022 Plan”) initially reserving 96,000 shares of the Company’s common stock for issuance thereunder. The 2022 Plan became effective on June 23, 2022 upon approval of the 2022 Plan by the Company’s shareholders at the Company’s annual meeting of shareholders. On June 2, 2023, the Company’s board of directors approved the Hoth Therapeutics, Inc. Amended and Restated 2022 Omnibus Equity Incentive Plan (the “Amended and Restated 2022 Plan”) which was approved by stockholders on August 18, 2023. Under the Amended and Restated 2022 Plan there are 591,317 shares of Company common stock available for grant. Restricted Stock Awards A summary of the Company’s restricted stock awards granted under the equity incentive plans during the years ended December 31, 2023 and 2022 is as follows: Number of Weighted Nonvested at December 31, 2021 100 $ 75.00 Granted 5,075 3.16 Vested (1,791 ) 7.17 Nonvested at December 31, 2022 3,384 $ 3.16 Vested (1,691 ) 3.16 Nonvested at December 31, 2023 1,693 $ 3.16 As of December 31, 2023, approximately $3,000 of unrecognized stock-based compensation expense was related to restricted stock awards. The weighted average remaining contractual term of unvested restricted stock awards was approximately 1.0 year at December 31, 2023. Stock Options During the year ended December 31, 2023, pursuant to and subject to the available number of shares reserved under the 2022 Plan, the Company issued an aggregate of 90,000 options to the Company’s employees and directors. The aggregate grant date fair value of these options was approximately $0.2 million. During the year ended December 31, 2022, pursuant to and subject to the available number of shares reserved under the 2018 Plan, the Company issued an aggregate of 51,800 options to the Company’s directors. The aggregate grant date fair value of these options was approximately $0.6 million. The fair value of options granted in 2023 and 2022 was estimated using the following assumptions: Year Ended December 31, 2023 2022 Exercise price $ 2.59 $ 14.75 Term (years) 10 10 Expected stock price volatility 105.00 % 96.10 % Risk-free rate of interest 4.02 % 2.10 % A summary of option activity under the Company’s stock option plan for the years ended December 31, 2023 and 2022 is presented below: Number of Weighted Total Weighted Outstanding as of December 31, 2021 52,851 84.15 — 8.6 Options issued 51,800 14.75 — 9.2 Outstanding as of December 31, 2022 104,651 49.80 — 8.3 Options expired (25,289 ) 46.10 — — Options issued 90,000 2.59 — 9.5 Outstanding as of December 31, 2023 169,362 26.78 — 8.4 Options vested and exercisable as of December 31, 2023 169,362 26.78 — 8.4 All outstanding stock options are fully vested. Stock Based Compensation Stock-based compensation expense for the years ended December 31, 2023 and 2022 was as follows: Year Ended December 31, 2023 2022 Employee and director stock option awards $ 182,522 $ 560,376 Employee and director restricted stock awards 7,734 7,836 Non-employee stock warrant awards 26,173 52,586 $ 216,428 $ 620,798 For the years ended December 31, 2023 and 2022, the amount of stock-based compensation expense included within research and development and general and administrative expenses was as follows: Year Ended December 31, 2023 2022 Research and development $ 26,172 $ 52,586 General and administrative 190,256 568,212 $ 216,428 $ 620,798 Warrants A summary of warrant activity for the years ended December 31, 2023 and 2022 is presented below: Number of Weighted Total Weighted Outstanding as of December 31, 2021 402,840 49.83 — 2.3 Outstanding as of December 31, 2022 402,840 49.83 — 1.4 Issued 6,165,725 2.61 — 4.5 Exercised (2,355,050 ) 0.00 — — Outstanding as of December 31, 2023 4,213,515 7.01 — 4.5 Warrants exercisable as of December 31, 2023 4,212,751 6.99 — 4.5 The Company has determined that the warrants should be accounted as a component of stockholders’ equity.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note 7-Commitments and Contingencies Office lease Effective November 2023, the Company leased office space for a two year term. The Company’s office lease contains a renewal option. The Company has evaluated several factors in assessing whether there is reasonable certainty that the Company will exercise its contractual renewal option concluding that it is not reasonably certain to exercise such option. As it is not reasonably certain to be exercised, the Company excluded the renewal term in determining the lease term used in calculating the right-of-use asset and lease liability. Prior to entering into this lease, the Company has not entered into any lease arrangements in excess of 12 months. The table below presents certain information related to the Company’s lease cost: Year Ended December 31, 2023 2022 Operating lease expense $ 5,464 $ — Short term lease expense $ 33,351 $ 66,834 Total lease cost $ 38,815 $ 66,834 Right-of-use asset and lease liability for operating leases were recorded in the consolidated balance sheets as follows: As of Assets Lease right of use assets $ 55,165 Total lease assets $ 55,165 Liabilities Current liabilities: Lease liability - current portion $ 28,839 Noncurrent liabilities: Lease liability, net of current portion $ 26,326 Total lease liability $ 55,165 Supplemental cash flow information related to the Company’s leases for the year ended December 31, 2023 were as follows: Cash paid for amounts included in the measurement of lease liabilities Operating cash flows for operating leases $ 5,464 The weighted-average remaining lease term for the operating lease is 1.8 years and the weighted-average incremental borrowing rate is 10% as of December 31, 2023. As of December 31, 2023, future minimum lease payments required under operating leases are as follows: 2024 $ 32,784 2025 27,320 Total minimum lease payments $ 60,104 Less: effects of discounting (4,939 ) Present value of future minimum lease payments $ 55,165 Litigation The Company is not currently a party to any material legal proceedings and is not aware of any pending or threatened claims. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2023
Income Taxes [Abstract]
Income taxes	Note 8-Income taxes The table below presents the components of the provision for taxes: The Company’s provision is primarily driven by the full valuation allowance in 2023 and 2022. As of December 31, 2023 2022 Current U.S. Federal $ - $ - U.S. State - - U.S. Foreign - - Total current provision Deferred - - U.S. Federal - - U.S. State - - U.S. Foreign - - Total deferred benefit - Change in valuation allowance - - Total provision for income taxes $ - $ - At December 31, 2023 and 2022, the tax effects of the temporary differences and carryforwards that give rise to deferred tax assets consist of the following: As of December 31, 2023 2022 Deferred tax assets Net operating loss carryforwards $ 11,926,158 $ 10,378,471 Research and development credits - - Capitalized research costs 2,272,029 1,211,477 Equity based compensation 549,587 670,035 Licenses acquired 266,091 338,239 Depreciation - - Accruals and other temporary differences 297,949 215,152 Total deferred tax assets 15,311,814 12,813,374 Less valuation allowance (15,311,814 ) (12,813,374 ) Deferred tax assets, net of allowance $ - $ - A reconciliation of the statutory income tax rates and the Company’s effective tax rate for the years ended December 31, 2023 and 2022 is as follows: Years Ended 2023 2022 Statutory federal income tax rate 21.0 % 21.0 % State taxes, net of federal benefit 10.3 % 9.5 % Impact of non-U.S. earnings 0.0 % 0.0 % Permanent items 0.0 % (0.9 )% Credits 0.8 % 0.0 % Equity compensation 0.0 % (0.1 )% Rate changes 0.0 % 0.0 % Foreign rate differential 0.1 % 0.0 % Previous tax year adjustment (0.2 )% 10.0 % Other 0.0 % 0.0 % Change in valuation allowance (32.0 )% (39.6 )% Total 0.0 % 0.0 % The Company has determined, based upon available evidence, that it is more likely than not that the net deferred tax assets will not be realized and, accordingly, has provided a full valuation allowance against its net deferred tax assets. As of December 31, 2023 and December 31, 2022, the Company has Federal net operating loss carryforwards of approximately $37.7 million and $32.9 million available to reduce future taxable income, if any, for Federal tax purposes. Approximately $1.5 million of Federal net operating losses can be carried forward to future tax years and expire in 2037. The Federal net operating loss generated during the years ended after December 31, 2017 of approximately $36.0 million can be carried forward indefinitely; however, the deduction for net operating losses incurred in tax years beginning after January 1, 2018 is limited to 80% of annual taxable income. In addition, the Company had approximately $0.5 million and $0.3 million of net operating losses at its subsidiary located in Australia, as of December 31, 2023 and December 31, 2022, respectively. As required by the 2017 Tax Cuts and Jobs Act and effective in 2022, the deferred tax asset as of December 31, 2023 and December 31, 20222, included $2.3 million and $1.2 million related to the mandatory capitalization of research and development expenses. On August 16, 2022, the Inflation Reduction Act of 2022 (“IRA”) was signed into law. The IRA increased and modified the qualified small business (“QSB”) payroll tax credit for increasing research activities. Provision 13902 of the IRA of 2022 increased the maximum amount of payroll tax research credit that a QSB can elect to apply against payroll tax liability from $250,000 to $500,000 for tax years beginning after December 31, 2022. This payroll tax credit is a creditable tax credit against the employer’s portion of social security taxes, and the IRA also modified IRC 3111(f) to allow a portion of the payroll tax credit to apply against the employer’s portion of Medicare tax. For the year ended December 31, 2023, the Company recorded $0.1 million of other income for the payroll tax credit and $0.2 million is still outstanding. The remaining research credit carryforward of $0.2 million will be utilized in the future as an offset against payroll taxes at the time the payroll tax is incurred. The utilization of the Company’s net operating loss carryforwards and research tax credit carryovers could be subject to annual limitations under Section 382 and 383 of the Internal Revenue Code of 1986, as amended (the “Code”), and similar state tax provisions, due to ownership change limitations that may have occurred previously or that could occur in the future. These ownership changes limit the amount of net operating loss carryforwards and other deferred tax assets that can be utilized to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section 382 and 383 of the Code, results from transactions increasing ownership of certain stockholders or public groups in the stock of the corporation by more than 50 percent points over a three-year period. The Company has not conducted an analysis of an ownership change under Section 382 of the Code. To the extent that a study is completed and an ownership change is deemed to occur, the Company’s net operating losses and tax credits could be limited. At December 31, 2023 and 2022, the Company did not have any significant uncertain tax positions. The Company will recognize interest and penalties related to uncertain tax positions, as applicable, in income tax expense. As of December 31, 2023 and 2022, the Company had no All of the Company’s tax years will remain open for examination by the Federal and state tax authorities from the date of utilization of the net operating loss. Management asserts that its foreign earnings are permanently reinvested, and therefore, have not provided deferred taxes on foreign cash. Additionally, no additional income taxes have been provided for any remaining undistributed foreign earnings not subject to the transition tax, or any additional outside basis differences inherent in our foreign subsidiaries, as these amounts continue to be indefinitely reinvested in foreign operations. The company will continue to monitor the foreign cash position as they maintain the assertion that foreign earnings are permanently reinvested.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstarct]
Subsequent Events	Note 9-Subsequent Events The Company has evaluated subsequent events and transactions that occurred up to the date the consolidated financial statements were issued. Based upon this review, except for as noted below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the consolidated financial statements. On January 4, 2024, the compensation committee of the board of directors increased the number of shares reserved for issuance under the 2018 Plan from 166,878 shares to 176,878 shares. On January 26, 2024, the Company provided 60 days notice to the George Washington University of its termination of the license agreement for its breath based diagnostic device. The license agreement terminated on March 26, 2024. On February 6, 2024, the Company received notice that its office lease was to be terminated. The Company and its landlord agreed to relocate its office space to another location under substantially the same terms and conditions as its existing lease. Monthly payments for the new office lease are unchanged and term of the lease expires in February 2026. On March 27, 2024, the Company entered into a warrant inducement agreement with a holder of certain of its existing warrants to immediately exercise for cash an aggregate 2,500,000 warrants to purchase shares of the Company’s common stock at a reduced exercise price of $1.6675 per share for gross proceeds to the Company of approximately $4.2 million. The exercised warrants were issued pursuant to a securities purchase agreement dated December 29, 2022, by and between the Company and a certain accredited investor. Each warrant was exercisable for a period of five and one-half years from the issuance date at an original exercise price of $5.00 per share. As an inducement to such exercise, the Company agreed to issue new unregistered warrants to purchase up to 3,750,000 shares of the Company’s common stock at an exercise price of $1.50 per share. The warrants are exercisable immediately upon issuance and will expire on July 3, 2028.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ (7,845,390)	$ (11,371,953)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2023
Significant Accounting Policies [Abstract]
Basis of presentation and principles of consolidation	Basis of presentation and principles of consolidation The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying consolidated financial statements include the accounts of the Company’s wholly-owned subsidiaries, merveille.ai which was incorporated under the laws of Nevada on October 4, 2023 and Hoth Therapeutics Australia Pty Ltd, which was incorporated under the laws of the State of Victoria in Australia on June 5, 2019. All significant intercompany balances and transactions have been eliminated in consolidation.
Reclassifications	Reclassifications Certain line items on the statement of operations and comprehensive loss for the year ended December 31, 2022 have been reclassified to conform to the current period presentation. Research and development - licenses acquired (including stock-based compensation) of $0.1 million was reclassified to research and development. Compensation and related expenses (including stock-based compensation) of $2.6 million, professional fees (including stock-based compensation) of $2.5 million, rent of $0.1 million, and other general and administrative expense of $1.0 million were consolidated into one general and administrative line item. Dividend income and realized and unrealized gains and losses have been separately presented within other income (expense), net. These reclassifications did not change our reported net loss or comprehensive loss for the year ended December 31, 2022.
Emerging growth company	Emerging growth company As an emerging growth company, the Company may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act of 1933, as amended, registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statement with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. However, beginning December 31, 2024, we will no longer be an “emerging growth company,” and will no longer have the ability to delay adoption of these new or revised accounting standards, or to take advantage of reduced corporate governance disclosures.
Use of estimates	Use of estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company’s consolidated financial statements relate to stock-based compensation and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.
Cash and cash equivalents	Cash and cash equivalents The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents. There were no cash equivalents as of December 31, 2023 and December 31, 2022, respectively. Cash held in foreign bank accounts totaled $0.1 million and $0.4 million as of December 31, 2023 and December 31, 2022, respectively.
Marketable securities	Marketable securities Marketable securities are classified as trading and are carried at fair value. The Company’s marketable securities consist of a mutual fund which is valued at a quoted market price.
Concentrations of credit risk and off-balance sheet risk	Concentrations of credit risk and off-balance sheet risk The Company has significant cash balances at financial institutions which, throughout the year, regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurements The fair value of the Company’s assets and liabilities, which would qualify as financial instruments under ASC Topic 820, approximates the carrying amounts represented in the Company’s balance sheet, primarily due to their short-term nature. The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. During the years ended December 31, 2023 and December 31, 2022, there were no changes in valuation techniques or transfers between Level 1, Level 2, and Level 3.
Leases	Leases The Company determines if an arrangement is a lease at inception and classifies its leases at commencement. Operating leases are presented as right-of-use (“ROU”) assets and the corresponding lease liabilities are included in lease liability, current and lease liability, on the Company’s balance sheets. ROU assets represent the Company’s right to use an underlying asset, and lease liabilities represent the Company’s obligation to make lease payments in exchange for the ability to use the asset for the duration of the lease term. The Company has lease agreements which contain both lease and non-lease components, which it has elected to account for as a single lease component. As such, minimum lease payments include fixed payments for non-lease components within a lease agreement but exclude variable lease payments not dependent on an index or rate, such as common area maintenance, operating expenses, utilities, or other costs that are subject to fluctuation from period to period. Certain of the leases contain an option to extend the term of the lease. The option to extend a lease is included in the lease term only when it is reasonably certain that the Company will elect that option. Additionally, the Company does not record ROU assets or lease liabilities for short-term leases that have a term of twelve months or less at lease commencement. ROU assets and lease liabilities are recognized at the commencement date and determined using the present value of the future minimum lease payments over the lease term. The Company uses an incremental borrowing rate based on an estimated rate of interest for collateralized borrowing since the Company’s leases do not include an implicit interest rate. The estimated incremental borrowing rate considers market data, actual lease economic environment, and the lease term at commencement date.
Investment in joint ventures	Investment in joint ventures Ownership interests in entities for which the Company has significant influence that are not consolidated are accounted for as equity method investments. SEC Staff Announcement: “Accounting for Limited Partnership Investments” (codified in ASC 323-30-S99-1) guidance requires the use of the equity method unless the investor’s interest “is so minor that the limited partner may have virtually no influence over partnership operating and financial policies.” The SEC staff’s position is that investments in limited partnerships of greater than 3% to 5% are considered more than minor and, therefore, should be accounted for using the equity method or fair value option. Investments accounted for using the equity method may be reported on a lag up to three months if financial statements of the investee are not available in sufficient time for the investor to apply the equity method as of the current reporting date. The determination of whether an investee’s results are recorded on a lag is made on an investment-by-investment basis. This investment in joint ventures is further described in Note 5 of these consolidated financial statements.
Accounts Payable	Accounts Payable For the year ended December 31, 2023, the Company’s subsidiary Hoth Therapeutics Australia Pty Ltd, recorded approximately a $260,000 gain due to a settlement agreement on a payable balance with Novotech, a clinical trial management vendor. The gain is recognized in the consolidated statements of operations and comprehensive loss following a manner consistent with how the expense was originally recorded.
Research and development costs	Research and development costs Research and development costs, including acquired in-process research and development expenses for which there is no alternative future use, are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.
Stock-based compensation	Stock-based compensation The Company accounts for share-based payment awards exchanged for services at the estimated grant date fair value of the award. Stock options issued under the Company’s long-term incentive plans are granted with an exercise price equal to no less than the market price of the Company’s stock at the date of grant and expire up to ten years from the date of grant. Options are generally issued fully vested. The Company accounts for forfeited awards as they occur. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. Expected Term Expected Volatility Risk-Free Interest Rate Expected Dividend The Company grants restricted stock awards under its equity incentive plan. Restricted stock awards are granted to employees and non-employees. The restricted stock awards are measured based on the grant-date fair value. In general, the restricted stock awards vest over a service period of zero to three years. Stock-based compensation expense is generally recognized based on the straight-line basis over the requisite service period and forfeitures are accounted for as they occur. The Company has issued warrants to non-employees. The warrants are measured based on the grant-date fair value. In general, the warrants vest over a term of zero to ten years. Stock-based compensation expense is generally recognized based on the straight-line basis over the vesting term.
Income taxes	Income taxes Income taxes are recorded in accordance with ASC 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.
Net loss per share	Net loss per share Net loss per share is computed by dividing net loss by the weighted average number of common stock outstanding during the period. Since the Company had a net loss in the periods presented, basic and diluted net loss per common share are the same. The following were excluded from the computation of diluted shares outstanding due to the losses for each period presented, as they would have had an anti-dilutive impact on the Company’s net loss: Year Ended December 31, Potentially dilutive securities 2023 2022 Warrants 4,213,515 402,840 Options 169,362 104,651 Non-vested restricted stock awards 1,693 3,384 Total 4,384,570 510,875
Recent accounting pronouncements	Recent accounting pronouncements Currently, management does not believe that any recently issued, but not yet effective accounting pronouncements, if currently adopted, would have a material impact on the Company’s consolidated financial statements.

Significant Accounting Polici_2

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2023
Significant Accounting Policies [Abstract]
Schedule of Anti-Dilutive Impact on the Company’s Net Loss	The following were excluded from the computation of diluted shares outstanding due to the losses for each period presented, as they would have had an anti-dilutive impact on the Company’s net loss: Year Ended December 31, Potentially dilutive securities 2023 2022 Warrants 4,213,515 402,840 Options 169,362 104,651 Non-vested restricted stock awards 1,693 3,384 Total 4,384,570 510,875

License Agreements (Tables)

License Agreements (Tables)	12 Months Ended
	Dec. 31, 2023
License Agreements [Abstract]
Schedule of Research and Development Expenses for Licenses Acquired	The following summarizes the Company’s research and development expenses for licenses acquired during the years ended December 31, 2023 and 2022: Year Ended December 31, 2023 2022 The George Washington University $ 66,172 $ 66,586 North Carolina State University — 27,500 Virginia Commonwealth University (275,000 ) — University of Cincinnati 7,500 7,500 Adjustment — (15,000 ) $ (201,328 ) $ 86,586

Fair Value of Financial Asset_2

Fair Value of Financial Assets and Liabilities (Tables)	12 Months Ended
	Dec. 31, 2023
Fair Value of Financial Assets and Liabilities [Abstract]
Schedule of Assets and Liabilities that are Measured at Fair Value	The following tables present the Company’s assets and liabilities that are measured at fair value at December 31, 2023 and 2022: Fair value measured at December 31, 2023 Total at Quoted Significant Significant Assets Marketable securities - mutual fund $ — $ — $ — $ — Investment in joint ventures $ 37,400 $ — $ — $ 37,400 Fair value measured at December 31, 2022 Total at Quoted (Level 1) Significant Significant (Level 3) Assets Marketable securities - mutual fund $ 209,320 $ 209,320 $ — $ — Investment in joint ventures $ 33,000 $ — $ — $ 33,000
Schedule of Changes in the Fair Value of the Company’s Level 3 Financial Assets	The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis: Investment in joint ventures at fair value at December 31, 2021 $ 410,000 Change in fair value of investments in joint ventures (377,000 ) Investment in joint ventures at fair value at December 31, 2022 33,000 Change in fair value of investments in joint ventures 4,400 Investment in joint ventures at fair value at December 31, 2023 $ 37,400

Stockholder_s Equity (Tables)

Stockholder’s Equity (Tables)	12 Months Ended
	Dec. 31, 2023
Stockholder’s Equity [Line Items]
Schedule of Restricted Stock Awards Granted	A summary of the Company’s restricted stock awards granted under the equity incentive plans during the years ended December 31, 2023 and 2022 is as follows: Number of Weighted Nonvested at December 31, 2021 100 $ 75.00 Granted 5,075 3.16 Vested (1,791 ) 7.17 Nonvested at December 31, 2022 3,384 $ 3.16 Vested (1,691 ) 3.16 Nonvested at December 31, 2023 1,693 $ 3.16
Schedule of Fair Value of Options Granted	The fair value of options granted in 2023 and 2022 was estimated using the following assumptions: Year Ended December 31, 2023 2022 Exercise price $ 2.59 $ 14.75 Term (years) 10 10 Expected stock price volatility 105.00 % 96.10 % Risk-free rate of interest 4.02 % 2.10 %
Schedule of Warrant Activity	A summary of option activity under the Company’s stock option plan for the years ended December 31, 2023 and 2022 is presented below: Number of Weighted Total Weighted Outstanding as of December 31, 2021 52,851 84.15 — 8.6 Options issued 51,800 14.75 — 9.2 Outstanding as of December 31, 2022 104,651 49.80 — 8.3 Options expired (25,289 ) 46.10 — — Options issued 90,000 2.59 — 9.5 Outstanding as of December 31, 2023 169,362 26.78 — 8.4 Options vested and exercisable as of December 31, 2023 169,362 26.78 — 8.4
Schedule of Stock-Based Compensation Expense	Stock-based compensation expense for the years ended December 31, 2023 and 2022 was as follows: Year Ended December 31, 2023 2022 Employee and director stock option awards $ 182,522 $ 560,376 Employee and director restricted stock awards 7,734 7,836 Non-employee stock warrant awards 26,173 52,586 $ 216,428 $ 620,798
Schedule of Stock-Based Compensation Expense Included Research and Development and General and Administrative Expenses	For the years ended December 31, 2023 and 2022, the amount of stock-based compensation expense included within research and development and general and administrative expenses was as follows: Year Ended December 31, 2023 2022 Research and development $ 26,172 $ 52,586 General and administrative 190,256 568,212 $ 216,428 $ 620,798
Warrant [Member]
Stockholder’s Equity [Line Items]
Schedule of Warrant Activity	A summary of warrant activity for the years ended December 31, 2023 and 2022 is presented below: Number of Weighted Total Weighted Outstanding as of December 31, 2021 402,840 49.83 — 2.3 Outstanding as of December 31, 2022 402,840 49.83 — 1.4 Issued 6,165,725 2.61 — 4.5 Exercised (2,355,050 ) 0.00 — — Outstanding as of December 31, 2023 4,213,515 7.01 — 4.5 Warrants exercisable as of December 31, 2023 4,212,751 6.99 — 4.5

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies [Abstract]
Schedule of Lease Cost	The table below presents certain information related to the Company’s lease cost: Year Ended December 31, 2023 2022 Operating lease expense $ 5,464 $ — Short term lease expense $ 33,351 $ 66,834 Total lease cost $ 38,815 $ 66,834
Schedule of Right-of-Use Asset and Lease Liability for Operating Leases	Right-of-use asset and lease liability for operating leases were recorded in the consolidated balance sheets as follows: As of Assets Lease right of use assets $ 55,165 Total lease assets $ 55,165 Liabilities Current liabilities: Lease liability - current portion $ 28,839 Noncurrent liabilities: Lease liability, net of current portion $ 26,326 Total lease liability $ 55,165
Schedule of Supplemental Cash Flow Information	Supplemental cash flow information related to the Company’s leases for the year ended December 31, 2023 were as follows: Cash paid for amounts included in the measurement of lease liabilities Operating cash flows for operating leases $ 5,464
Schedule of Future Minimum Lease Payments	As of December 31, 2023, future minimum lease payments required under operating leases are as follows: 2024 $ 32,784 2025 27,320 Total minimum lease payments $ 60,104 Less: effects of discounting (4,939 ) Present value of future minimum lease payments $ 55,165

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income Taxes [Abstract]
Schedule of Valuation Allowance	The Company’s provision is primarily driven by the full valuation allowance in 2023 and 2022. As of December 31, 2023 2022 Current U.S. Federal $ - $ - U.S. State - - U.S. Foreign - - Total current provision Deferred - - U.S. Federal - - U.S. State - - U.S. Foreign - - Total deferred benefit - Change in valuation allowance - - Total provision for income taxes $ - $ -
Schedule of Deferred Tax Assets	At December 31, 2023 and 2022, the tax effects of the temporary differences and carryforwards that give rise to deferred tax assets consist of the following: As of December 31, 2023 2022 Deferred tax assets Net operating loss carryforwards $ 11,926,158 $ 10,378,471 Research and development credits - - Capitalized research costs 2,272,029 1,211,477 Equity based compensation 549,587 670,035 Licenses acquired 266,091 338,239 Depreciation - - Accruals and other temporary differences 297,949 215,152 Total deferred tax assets 15,311,814 12,813,374 Less valuation allowance (15,311,814 ) (12,813,374 ) Deferred tax assets, net of allowance $ - $ -
Schedule of Statutory Income Tax Rates and Effective Tax Rate	A reconciliation of the statutory income tax rates and the Company’s effective tax rate for the years ended December 31, 2023 and 2022 is as follows: Years Ended 2023 2022 Statutory federal income tax rate 21.0 % 21.0 % State taxes, net of federal benefit 10.3 % 9.5 % Impact of non-U.S. earnings 0.0 % 0.0 % Permanent items 0.0 % (0.9 )% Credits 0.8 % 0.0 % Equity compensation 0.0 % (0.1 )% Rate changes 0.0 % 0.0 % Foreign rate differential 0.1 % 0.0 % Previous tax year adjustment (0.2 )% 10.0 % Other 0.0 % 0.0 % Change in valuation allowance (32.0 )% (39.6 )% Total 0.0 % 0.0 %

Organization and Description _2

Organization and Description of Business Operations (Details) - USD ($) $ / shares in Units, $ in Millions		12 Months Ended
	Sep. 13, 2023	Dec. 31, 2023
Organization and Description of Business Operations (Details) [Line Items]
Shares of common stock (in Shares)	549,275
Common stock, shares purchase (in Shares)	550,725
Common stock, purchase price	$ 2.629
Warrants to purchase (in Shares)	1,100,000
Aggregate gross proceeds (in Dollars)	$ 2.9
Exercise price, per share	$ 2.505
Date of incorporation		May 16, 2017
Common Stock [Member]
Organization and Description of Business Operations (Details) [Line Items]
Common stock, purchase price	2.63
Pre-Funded Warrant [Member]
Organization and Description of Business Operations (Details) [Line Items]
Exercise price, per share	0.001
Wainwright Warrants [Member]
Organization and Description of Business Operations (Details) [Line Items]
Exercise price, per share	$ 3.2875
Purchase of shares (in Shares)	55,000

Significant Accounting Polici_3

Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Significant Accounting Policies [Line Items]
Reclassified to research and development	$ 100,000
Compensation and related expenses	2,600,000
Professional fees	2,500,000
Rent	100,000
General and administrative expense	1,000,000
Bank accounts	100,000	$ 400,000
Federally insured limit	250,000
Accounts Payable	$ 260,000
Minimum [Member] | Limited Partnership [Member]
Significant Accounting Policies [Line Items]
Limited partnership, percentage	3%
Maximum [Member] | Limited Partnership [Member]
Significant Accounting Policies [Line Items]
Limited partnership, percentage	5%

Significant Accounting Polici_4

Significant Accounting Policies (Details) - Schedule of Anti-Dilutive Impact on the Company’s Net Loss - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Anti-Dilutive Impact on the Company’s Net Loss [Line Items]
Total Anti-dilutive	4,384,570	510,875
Warrants [Member]
Schedule of Anti-Dilutive Impact on the Company’s Net Loss [Line Items]
Total Anti-dilutive	4,213,515	402,840
Options [Member]
Schedule of Anti-Dilutive Impact on the Company’s Net Loss [Line Items]
Total Anti-dilutive	169,362	104,651
Non-vested restricted stock awards [Member]
Schedule of Anti-Dilutive Impact on the Company’s Net Loss [Line Items]
Total Anti-dilutive	1,693	3,384

License Agreements (Details)

License Agreements (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
License Agreements [Line Items]
Recorded an expense	$ 29,000	$ 53,000
License maintenance fee	7,500	14,000
Principal amount	$ 150,000	$ 150,000
Annual minimum payments, term	5 years	5 years
Annual maintenance fees	$ 125,000	$ 125,000
Annual license maintenance fee	2,500	2,500
Minimum annual royalty fee	5,000	5,000
GW Patent License Agreement [Member]
License Agreements [Line Items]
Recorded an expense	30,000
North Carolina State University [Member]
License Agreements [Line Items]
License fee	$ 0	$ 28,000

License Agreements (Details) -

License Agreements (Details) - Schedule of Research and Development Expenses for Licenses Acquired - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Research and Development Expenses for Licenses Acquired [Line Items]
Research and development expense	$ (201,328)	$ 86,586
The George Washington University [Member]
Schedule of Research and Development Expenses for Licenses Acquired [Line Items]
Research and development expense	66,172	66,586
North Carolina State University [Member]
Schedule of Research and Development Expenses for Licenses Acquired [Line Items]
Research and development expense		27,500
Virginia Commonwealth University [Member]
Schedule of Research and Development Expenses for Licenses Acquired [Line Items]
Research and development expense	(275,000)
University of Cincinnati [Member]
Schedule of Research and Development Expenses for Licenses Acquired [Line Items]
Research and development expense	7,500	7,500
Adjustment [Member]
Schedule of Research and Development Expenses for Licenses Acquired [Line Items]
Research and development expense		$ (15,000)

Note Receivable (Details)

Note Receivable (Details) - USD ($)	Oct. 21, 2022	Sep. 10, 2022	Sep. 10, 2020
Note Receivable [Line Items]
Convertible promissory note			$ 50,000
Accrued interest rate		6%
Accrued interest	$ 6,000
Isoprene Pharmaceuticals, Inc [Member]
Note Receivable [Line Items]
Convertible promissory note	$ 50,000

Fair Value of Financial Asset_3

Fair Value of Financial Assets and Liabilities (Details) - USD ($)		1 Months Ended	12 Months Ended
	May 28, 2020	Mar. 28, 2020	Dec. 31, 2023	Dec. 31, 2022	Dec. 06, 2021	May 04, 2020	Mar. 27, 2020
Fair Value of Financial Assets and Liabilities [Line Items]
Option inclusive amount							$ 250,000
Interest purchase agreement		1%
Purchase price	$ 100,000
Impairment charge			$ 400,000
Investment			0	$ 0
Unrealized gain loss on this investment				(567,692)
Gain (Loss) on Investments				(567,692)
Investment value			$ 37,400	$ 33,000
Class B common stock [Member]
Fair Value of Financial Assets and Liabilities [Line Items]
Shares issued (in Shares)					100,000	120,000
Common stock value						$ 60,000
Common stock per share (in Dollars per share)			$ 0.17	$ 0.15
HaloVax’s [Member]
Fair Value of Financial Assets and Liabilities [Line Items]
Outstanding membership interests							5%
Outstanding membership interests							$ 250,000
Investment in HaloVax [Member]
Fair Value of Financial Assets and Liabilities [Line Items]
Outstanding membership interests							25%
Outstanding membership interests							$ 3,000,000
Zylö [Member]
Fair Value of Financial Assets and Liabilities [Line Items]
Unrealized gain loss on this investment			$ 4,400	$ 4,400
Gain (Loss) on Investments			$ 27,000	$ 27,000

Fair Value of Financial Asset_4

Fair Value of Financial Assets and Liabilities (Details) - Schedule of Assets and Liabilities that are Measured at Fair Value - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Assets
Marketable securities - mutual fund		$ 209,320
Investment in joint ventures	37,400	33,000
Quoted prices in active markets (Level 1) [Member]
Assets
Marketable securities - mutual fund		209,320
Investment in joint ventures
Significant other observable inputs (Level 2) [Member]
Assets
Marketable securities - mutual fund
Investment in joint ventures
Significant unobservable inputs (Level 3) [Member]
Assets
Marketable securities - mutual fund
Investment in joint ventures	$ 37,400	$ 33,000	$ 410,000

Fair Value of Financial Asset_5

Fair Value of Financial Assets and Liabilities (Details) - Schedule of Changes in the Fair Value of the Company’s Level 3 Financial Assets - Level 3 Fnancial Assets [Member] - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Changes in the Fair Value of the Company’s Level 3 Financial Assets [Line Items]
Investment in joint ventures at fair value at starting	$ 33,000	$ 410,000
Change in fair value of investments in joint ventures	4,400	(377,000)
Investment in joint ventures at fair value at ending	$ 37,400	$ 33,000

Stockholder_s Equity (Details)

Stockholder’s Equity (Details) - USD ($)

1 Months Ended

12 Months Ended

Mar. 27, 2024

Jan. 04, 2024

Sep. 13, 2023

Jan. 11, 2023

Nov. 02, 2022

Apr. 14, 2022

Mar. 24, 2022

Feb. 02, 2022

Jun. 24, 2021

Dec. 29, 2022

Dec. 31, 2023

Dec. 31, 2022

Dec. 12, 2022

Stockholder’s Equity [Line Items]

Preferred stock, shares authorized

10,000,000

10,000,000

Preferred stock, par value (in Dollars per share)

$ 0.0001

$ 0.0001

Common stock, shares authorized

50,000,000

50,000,000

Share of common stock

549,275

Purchase of warrants

1,100,000

Warrant is exercisable period

5 years

Exercise price per share (in Dollars per share)

$ 2.505

Purchase of share

2,500,000

Purchase price per share (in Dollars per share)

$ 5

Accompanying warrant per share (in Dollars per share)

$ 0.001

Aggregate gross proceed amount (in Dollars)

$ 10,000,000

Warrant issuance description

Each December Common Stock Warrant is exercisable for a period of five and one-half years from the issuance date at an exercise price of $5.00 per share, subject to adjustment, and may, under certain circumstances, be exercised on a cashless basis.

Aggregate of shares

90,000

51,800

Unrecognized stock-based compensation expense (in Dollars)

$ 3,000

Unrecognized stock-based compensation term

1 year

Stock Issued, Value, Stock Options Exercised, Net of Tax Benefit (Expense) (in Dollars)

$ 200,000

$ 600,000

Securities Purchase Agreement [Member]

Stockholder’s Equity [Line Items]

Share of common stock

140,000

Common Stock [Member]

Stockholder’s Equity [Line Items]

Purchase of stock

689,275

Minimum [Member] | Common Stock [Member]

Stockholder’s Equity [Line Items]

Common stock, shares authorized

3,000,000

Maximum [Member] | Common Stock [Member]

Stockholder’s Equity [Line Items]

Common stock, shares authorized

50,000,000

Warrant [Member]

Stockholder’s Equity [Line Items]

Warrants exercise price (in Dollars per share)

3.2875

Pre-Funded Warrant [Member]

Stockholder’s Equity [Line Items]

Exercise price per share (in Dollars per share)

0.001

Purchase of share

1,860,000

Pre-Funded Warrant [Member] | Securities Purchase Agreement [Member]

Stockholder’s Equity [Line Items]

Price per share (in Dollars per share)

$ 2.629

Private Placement [Member]

Stockholder’s Equity [Line Items]

Proceeds from warrants (in Dollars)

$ 2,900,000

Placement Agent Warrant [Member]

Stockholder’s Equity [Line Items]

Warrants exercise price (in Dollars per share)

$ 0.001

Public Offering of Securities [Member]

Stockholder’s Equity [Line Items]

Warrant issuance description

The December Wainwright Warrants are exercisable for a period of five and one-half years from the issuance date at an exercise price of $6.25 per share, subject to adjustment, and may, under certain circumstances, be exercised on a cashless basis.

Underwritten public offering

329,412

Public offering price (in Dollars per share)

$ 21.25

Purchase of additional shares

49,412

Net proceeds (in Dollars)

$ 6,000,000

Series A Convertible Preferred Stock [Member]

Stockholder’s Equity [Line Items]

Preferred stock, par value (in Dollars per share)

$ 0.0001

$ 0.0001

Series B Convertible Preferred Stock [Member]

Stockholder’s Equity [Line Items]

Preferred stock, shares authorized

2,000,000

Preferred stock, par value (in Dollars per share)

$ 0.0001

$ 0.0001

$ 0.0001

Sale of stock

2,000,000

Aggregate purchase price (in Dollars)

$ 1,000

Aggregate price (in Dollars)

$ 10

Preferred stock designated

100,000

Series B Convertible Preferred Stock [Member] | Minimum [Member]

Stockholder’s Equity [Line Items]

Common stock, shares authorized

3,000,000

Series B Convertible Preferred Stock [Member] | Maximum [Member]

Stockholder’s Equity [Line Items]

Common stock, shares authorized

50,000,000

Common Stock [Member]

Stockholder’s Equity [Line Items]

Purchase of stock

550,725

Price per share (in Dollars per share)

$ 2.63

Subsequent Event [Member]

Stockholder’s Equity [Line Items]

Proceeds from warrants (in Dollars)

$ 4,200,000

Shares issued

3,750,000

Warrants exercise price (in Dollars per share)

$ 1.6675

Subsequent Event [Member] | Minimum [Member]

Stockholder’s Equity [Line Items]

Common stock reserved

166,878

Subsequent Event [Member] | Maximum [Member]

Stockholder’s Equity [Line Items]

Common stock reserved

176,878

Subsequent Event [Member] | Warrant [Member]

Stockholder’s Equity [Line Items]

Shares issued

2,500,000

Warrants exercise price (in Dollars per share)

$ 1.5

Board Of Directors [Member] | Series A Convertible Preferred Stock [Member]

Stockholder’s Equity [Line Items]

Preferred stock, shares authorized

5,000,000

Board Of Directors [Member] | Series B Convertible Preferred Stock [Member]

Stockholder’s Equity [Line Items]

Preferred stock, shares authorized

2,000,000

2018 Plan [Member]

Stockholder’s Equity [Line Items]

Aggregate of shares

26,878

Common stock reserved

66,878

2018 Plan [Member] | Minimum [Member]

Stockholder’s Equity [Line Items]

Issuance of share

156,878

146,878

66,878

2018 Plan [Member] | Maximum [Member]

Stockholder’s Equity [Line Items]

Issuance of share

166,878

156,878

146,878

2018 Plan [Member] | Subsequent Event [Member] | Minimum [Member]

Stockholder’s Equity [Line Items]

Issuance of share

166,878

2018 Plan [Member] | Subsequent Event [Member] | Maximum [Member]

Stockholder’s Equity [Line Items]

Issuance of share

176,878

2022 Equity Incentive Plan [Member]

Stockholder’s Equity [Line Items]

Issuance of share

96,000

Restated 2022 Plan [Member]

Stockholder’s Equity [Line Items]

Common stock available for grant

591,317

H.C. Wainwright & Co., LLC warrants [Member]

Stockholder’s Equity [Line Items]

Shares issued

55,000

Stockholder_s Equity (Details)

Stockholder’s Equity (Details) - Schedule of Restricted Stock Awards Granted - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Restricted Stock Awards Granted [Abstract]
Number of Restricted Stock Awards, Nonvested at Beginning Balance	3,384	100
Weighted Average Grant Day Fair Value, Nonvested at Beginning Balance	$ 3.16	$ 75
Number of Restricted Stock Awards,Granted		5,075
Weighted Average Grant Day Fair Value, Granted		$ 3.16
Number of Restricted Stock Awards, Vested	(1,691)	(1,791)
Weighted Average Grant Day Fair Value, Vested	$ 3.16	$ 7.17
Number of Restricted Stock Awards, Nonvested at Ending Balance	1,693	3,384
Weighted Average Grant Day Fair Value, Nonvested at Ending Balance	$ 3.16	$ 3.16

Stockholder_s Equity (Details_2

Stockholder’s Equity (Details) - Schedule of Fair Value of Options Granted Assumptions - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Fair Value of Options Granted Assumptions [Abstract]
Exercise price (in Dollars per share)	$ 2.59	$ 14.75
Term (years)	10 years	10 years
Expected stock price volatility	105%	96.10%
Risk-free rate of interest	4.02%	2.10%

Stockholder_s Equity (Details_3

Stockholder’s Equity (Details) - Schedule of Stock Option Activity - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Stock Option Plan [Abstract]
Number of Shares Options expired	(25,289)
Weighted Average Exercise Price Options expired	$ 46.1
Total Intrinsic Value Options expired
Weighted Average Remaining Contractual Life (in years) Options expired
Number of Shares, Options issued	90,000	51,800
Weighted Average Exercise Price, Options issued	$ 2.59	$ 14.75
Total Intrinsic Value, Options issued
Weighted Average Remaining Contractual Life (in years), Options issued	9 years 6 months	9 years 2 months 12 days
Number of Shares, Outstanding as of ending Balance	169,362	104,651	52,851
Weighted Average Exercise Price, Outstanding as of ending Balance	$ 26.78	$ 49.8	$ 84.15
Total Intrinsic Value, Outstanding as of ending Balance
Weighted Average Remaining Contractual Life (in years), Outstanding as of ending Balance	8 years 4 months 24 days	8 years 3 months 18 days	8 years 7 months 6 days
Number of Shares, Options vested and exercisable	169,362
Weighted Average Exercise Price, Options vested and exercisable	$ 26.78
Total Intrinsic Value, Options vested and exercisable
Weighted Average Remaining Contractual Life (in years), Options vested and exercisable	8 years 4 months 24 days

Stockholder_s Equity (Details_4

Stockholder’s Equity (Details) - Schedule of Stock-Based Compensation Expense - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Stock-Based Compensation Expense [Line Items]
Stock-based compensation expense, total	$ 216,428	$ 620,798
Employee stock option awards [Member]
Schedule of Stock-Based Compensation Expense [Line Items]
Stock-based compensation expense, total	182,522	560,376
Employee restricted stock awards [Member]
Schedule of Stock-Based Compensation Expense [Line Items]
Stock-based compensation expense, total	7,734	7,836
Non-employee stock warrant awards [Member]
Schedule of Stock-Based Compensation Expense [Line Items]
Stock-based compensation expense, total	$ 26,173	$ 52,586

Stockholder_s Equity (Details_5

Stockholder’s Equity (Details) - Schedule of Stock-Based Compensation Expense Included Research and Development and General and Administrative Expenses - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Stock-Based Compensation Expense Included Research and Development and General and Administrative Expenses [Line Items]
Stock-based compensation expense	$ 216,428	$ 620,798
Research and Development [Member]
Schedule of Stock-Based Compensation Expense Included Research and Development and General and Administrative Expenses [Line Items]
Stock-based compensation expense	26,172	52,586
General and Administrative [Member]
Schedule of Stock-Based Compensation Expense Included Research and Development and General and Administrative Expenses [Line Items]
Stock-based compensation expense	$ 190,256	$ 568,212

Stockholder_s Equity (Details_6

Stockholder’s Equity (Details) - Schedule of Warrant Activity - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Warrant Activity [Abstract]
Number of Warrants, Outstanding as of Ending Balance	4,213,515	402,840	402,840
Weighted Average Exercise Price, Outstanding as of Ending Balance	$ 7.01	$ 49.83	$ 49.83
Total Intrinsic Value, Outstanding as of Ending Balance
Weighted Average Remaining Contractual Life (in years), Outstanding as of Ending Balance	4 years 6 months	1 year 4 months 24 days	2 years 3 months 18 days
Number of Warrants, Warrants exercisable	4,212,751
Weighted Average Exercise Price, Warrants exercisable	$ 6.99
Total Intrinsic Value, Warrants exercisable
Weighted Average Remaining Contractual Life (in years), Warrants exercisable	4 years 6 months
Number of Warrants, Issued	6,165,725
Weighted Average Exercise Price, Issued	$ 2.61
Total Intrinsic Value, Issued
Weighted Average Remaining Contractual Life (in years), Issued	4 years 6 months
Number of Warrants, Exercised	(2,355,050)
Weighted Average Exercise Price, Exercised	$ 0
Total Intrinsic Value, Exercised
Weighted Average Remaining Contractual Life (in years), Exercised

Commitments and Contingencies_2

Commitments and Contingencies (Details)		12 Months Ended
	Nov. 30, 2023	Dec. 31, 2023
Commitments and Contingencies [Abstract]
Leased office space term	two
Weighted average remaining lease term		1 year 9 months 18 days
Weighted average incremental borrowing rate		10%

Commitments and Contingencies_3

Commitments and Contingencies (Details) - Schedule of Lease Cost - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Lease Cost [Abstract]
Operating lease expense	$ 5,464
Short term lease expense	33,351	66,834
Total lease cost	$ 38,815	$ 66,834

Commitments and Contingencies_4

Commitments and Contingencies (Details) - Schedule of Right-of-Use Asset and Lease Liability for Operating Leases - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Assets
Lease right of use assets	$ 55,165
Total lease assets	55,165
Liabilities
Lease liability - current portion	28,839
Lease liability, net of current portion	26,326
Total lease liability	$ 55,165

Commitments and Contingencies_5

Commitments and Contingencies (Details) - Schedule of Supplemental Cash Flow Information	12 Months Ended
	Dec. 31, 2023 USD ($)
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases	$ 5,464

Commitments and Contingencies_6

Commitments and Contingencies (Details) - Schedule of Future Minimum Lease Payments - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Schedule of Future Minimum Lease Payments [Abstract]
2024	$ 32,784
2025	27,320
Total minimum lease payments	60,104
Less: effects of discounting	(4,939)
Present value of future minimum lease payments	$ 55,165

Income Taxes (Details)

Income Taxes (Details) - USD ($)		1 Months Ended	12 Months Ended
	Dec. 31, 2017	Jan. 31, 2018	Dec. 31, 2023	Dec. 31, 2022
Income Taxes [Line Items]
Federal net operating loss carryforwards			$ 37,700,000	$ 32,900,000
Federal net operating losses carried forward			1,500,000
Federal net operating loss carryforwards	$ 36,000,000
Annual taxable income		80%
Net operating loss			500,000
Deferred tax asset expenses			2,300,000	1,200,000
Other income for the payroll tax credit			100,000
Tax credit outstanding			200,000
Research credit carryforward			200,000
Accrued interest or penalties
Australia [Member]
Income Taxes [Line Items]
Net operating loss				300,000
Minimum [Member]
Income Taxes [Line Items]
Payroll tax liability				250,000
Maximum [Member]
Income Taxes [Line Items]
Payroll tax liability				$ 500,000

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of Valuation Allowance - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Current
U.S. Federal
U.S. State
U.S. Foreign
Total current provision
Deferred
U.S. Federal
U.S. State
U.S. Foreign
Total deferred benefit
Change in valuation allowance
Total provision for income taxes

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of Deferred Tax Assets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Deferred tax assets
Net operating loss carryforwards	$ 11,926,158	$ 10,378,471
Research and development credits
Capitalized research costs	2,272,029	1,211,477
Equity based compensation	549,587	670,035
Licenses acquired	266,091	338,239
Depreciation
Accruals and other temporary differences	297,949	215,152
Total deferred tax assets	15,311,814	12,813,374
Less valuation allowance	(15,311,814)	(12,813,374)
Deferred tax assets, net of allowance

Income Taxes (Details) - Sche_3

Income Taxes (Details) - Schedule of Statutory Income Tax Rates and Effective Tax Rate	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Statutory Income Tax Rates and Effective Tax Rate [Abstract]
Statutory federal income tax rate	21%	21%
State taxes, net of federal benefit	10.30%	9.50%
Impact of non-U.S. earnings	0%	0%
Permanent items	0%	(0.90%)
Credits	0.80%	0%
Equity compensation	0%	(0.10%)
Rate changes	0%	0%
Foreign rate differential	0.10%	0%
Previous tax year adjustment	(0.20%)	10%
Other	0%	0%
Change in valuation allowance	(32.00%)	(39.60%)
Total	0%	0%

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Millions	Mar. 27, 2024	Jan. 26, 2024	Jan. 04, 2024	Sep. 13, 2023
Stockholders Equity [Line Item]
Termination of the license agreement notice period.		60 days
Subsequent Event [Member]
Stockholders Equity [Line Item]
Warrant to purchase	3,750,000
Warrant exercise price (in Dollars per share)	$ 1.6675
Gross proceeds (in Dollars)	$ 4.2
Exercise price per share (in Dollars per share)	$ 5
Subsequent Event [Member] | Minimum [Member]
Stockholders Equity [Line Item]
Number of shares reserved for issuance			166,878
Subsequent Event [Member] | Maximum [Member]
Stockholders Equity [Line Item]
Number of shares reserved for issuance			176,878
Warrant [Member]
Stockholders Equity [Line Item]
Warrant exercise price (in Dollars per share)				$ 3.2875
Warrant [Member] | Subsequent Event [Member]
Stockholders Equity [Line Item]
Warrant to purchase	2,500,000
Warrant exercise price (in Dollars per share)	$ 1.5